ReNerve's products are far superior to OCC. All the R&D is done for the conduit and the "game changer" graft.
FDA will come in due course for the conduit and then the graft.
The IPO will see them fully funded for the next 2 years
The last Cap Raises were done at .20 - .20 - .16 - .12
Once the sellers are done from the .16c cap raises (and maybe some from .12), then there will be no resistance to the price increasing.
This stock will dwarf OCC.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.020(20.0%) |
Mkt cap ! $13.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 12.0¢ | 10.0¢ | $9.015K | 80.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56000 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 147679 | 5 |
View Market Depth
| Last trade - 16.13pm 28/07/2025 (20 minute delay) ? |
| RNV (ASX) Chart |